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Genetic defects of the retina or retinal pigment epithelium(RPE) cause a substantial number of sight-impairing or
blinding disorders, many of which eventually cause the
degeneration and death of the visual cells.1,2 Previously
considered incurable, some of these retinal diseases can now
be treated, at least experimentally, by gene therapy.
This new era of retinal therapeutics followed the successful
restoration of retinal function in a canine model of RPE65 Leber
congenital amaurosis (LCA) through adeno-associated virus 2
(AAV2) vector-mediated gene augmentation targeting the RPE
layer of the eye.3 Restoring isomerohydrolase activity in the RPE
corrected the retinoid visual cycle and vision defect. When
treated at the predegenerate disease stage, treatment was both
effective and permanent, and photoreceptor structure was
preserved.4,5 Validation studies by other groups in both large6
and small7,8 animal models, along with preclinical safety studies
in nonhuman primates (NPHs) and dogs,9,10 confirmed that the
treatment was safe and effective. A further series of detailed
studies in patients and animal models established the dependence
of human cone photoreceptors on RPE65 isomerase,11 deter-
mined that the remaining photoreceptors in blind eyes were
amenable to treatment,12–14 showed that the visual cortex in man
and dog was intact and responsive in spite of early blindness,15
and developed outcome measures that could be used readily to
assess treatment outcomes.16,17 These studies were followed by
three independent clinical trials showing the treatment to be
safe.18–21 Since then, additional RPE65-LCA clinical trials have
been initiated both in academic settings and through commercial
entities in the United States and elsewhere (https://clinicaltrials.
gov/ct2/results?cond¼Leberþcongenitalþamaurosis&term¼RPE6,
in the public domain). To date, LCA remains the only blinding
genetic disease to be successfully treated in humans.
While the early successes in the treatment of LCA were
clearly encouraging, it appears that these gene therapy effects
do not last ‘‘forever.’’ Despite functional recovery in treated
areas, two studies now have shown continual loss of
photoreceptors22 with the structural phenotype of treated
areas eventually becoming comparable to untreated regions.5,23
Similar results were obtained in the canine model when
treatment was delayed until degeneration had begun, a
situation comparable to what occurs in human patients.5 This
series of discoveries at the level of a human clinical trial
indicates there can be unexpected pitfalls even in the most well
thought through studies. The RPE65 gene therapy trials show
that even when there is strong evidence of efficacy early after
treatment, it cannot be assumed that it will be long lasting. The
same care given to defining efficacy in the short term should be
used to define the longevity of the treatment success. Thus it is
important to emphasize the need to properly assess the
treatment outcomes in relation to the natural history of the
disease before claiming the success of a putative treatment.
In this overview, I will present concepts and strategies
relevant to developing and translating retinal gene therapeutics.
These range from selection of the animal model and the
therapeutic vector/promoter combination to application of the
model system to address translationally relevant questions.
ANIMAL MODELS
In vivo studies in animal models are the essential proof-of-
concept first step to establish efficacy of a treatment paradigm.
In addition to being a bona fide disease homologue, that is,
caused by the mutations in the same gene with expression in
the same target cell(s), the models should have a proportionally
comparable disease time course. Ideally, the model disease
should be ‘‘fast enough’’ that the therapeutic outcome can be
assessed in a reasonable time scale, but ‘‘not too fast and
overwhelming’’ such that efficacy cannot be established and
that the disease bears no resemblance to the human disorder.
Naturally occurring or genetically engineered models have been
the basic toolbox used for examining cellular and molecular
mechanisms of gene function and disease, and for developing
retinal therapeutics. These animal models cover the size
spectrum from Drosophila24 to cow25 and horse,26 and include
all sizes and species in between. In biology and experimental
medicine, the models have been arbitrarily divided into large
(‡dog or cat) and small, with small almost exclusively referring
to rodents. As a veterinarian, this division is somewhat ironic
given that the model system for my studies is the dog and that
in veterinary medicine dogs and cats are considered ‘‘small
animals.’’
For retinal disease studies and for the development and
testing of novel therapies, the dog is an ideal intermediate
model between mouse and man, as it is well suited to
facilitating translational studies. Indeed, in cases where the
appropriate model exists, experimental studies in the dog have
led the way to clinical trials (RPE65-LCA, CNGB3-ACHM, and
RPGR-XLRP), or trials in the late stages for Food and Drug
Administration pre-IND (investigational new drugs) application
(BEST1-BVMD) (Table 1). Moreover, with the development and
application of new genomic tools, there has been a marked
acceleration of disease gene discovery, and a combination of
genome-wide association studies (GWAS) along with next-
generation sequencing of whole genomes or exomes has
facilitated progress in identifying additional genetic models of
disease (Fig. 1). The identified mutations affect both the retinal
pigment epithelium (RPE) and the rod and/or cone photore-
ceptors, with defects involving members of the phototrans-
duction cascade, integral outer segment disc proteins, and the
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photoreceptor sensory cilium, as well as other structures (for
review see Refs. 27, 28). These models represent bona fide
human disease homologues where the disease phenotype in
model and man are the same. Selected examples include
RPE65-LCA,3,5,29 BEST1-BVMD,30–32 CNGB3- and CNGA3-
achromatopsia,33,34 RHO-ADRP,35 RPGR-XLRP,32,36–38 and
NPHP5-LCA.39
Quite apart from the particular merits of any individual
disease model, the dog and the canine eye offer advantages for
a broad range of translational studies. Because of its life span
and the time course of the diseases, disease progression in the
dog more closely resembles that of humans than do similar
smaller laboratory animal disease models. Furthermore, as the
size of canine and human eyes is similar,40 viral vectors or
drugs can be injected using the same surgical approaches and
dose volumes, and implantation of devices (e.g., retinal
prostheses or for sustained delivery of therapeutic agents) is
identical to those intended for human trials.3,41,42 In addition,
the instruments and methods for surgical intervention and in
vivo outcome assessments are comparable. Lastly, the recently
identified fovea-like region within the canine retina has a
similar cone density to the human and nonhuman primate
(NHP) fovea, and is equally susceptible to inherited macular
diseases, making it an ideal model system to study macular
degenerations and therapies.32
It is critical to emphasize, however, that regardless of their
translational value, the canine models are not alternatives to
other laboratory model systems such as rodents. Rather they
are a complementary and synergistic model, serving as an
intermediate between rodents and man that provides an
excellent test bed to develop or test new therapies. The
history of the field clearly demonstrates that progress toward
therapy of human patients has been served best by judicious
use of a comprehensive set of model systems among which are
rodent, canine, and others.
VECTORS, PROMOTERS, AND TRANSLATIONAL
APPLICATIONS
A critical issue that must be addressed during development of
proof-of-concept gene therapy studies in animal models is to
determine whether the results obtained with a vector–promoter
combination used in the animal can be directly applied to
patients in subsequent clinical trials. While this has been
possible in the case of the RPE65-LCA, in most cases the vector-
TABLE 1. Proof-of-Concept Studies in Dogs for Translational Applications; Comparison With Similar Studies in Mice, and Dates the Studies Were
Published
Species Leber Cong Am, RPE65 Achromatopsia, CNGB3 X-Linked RP, RPGR Best Disease, BEST1 Leber Cong Am, NPHP5
Dog Acland et al., 20013 Komaromy et al., 2007*,
201048
Beltran et al., 2012,
201550,68
Guziewicz et al., 2011†,
201344
Aguirre et al., 2016‡
Mouse Rakoczy et al., 20037 Carvalho et al., 201186 Wu et al., 201587 NR NR
Leber Cong Am, Leber congenital amaurosis; NR, not reported.
* Komaromy AM, et al. IOVS 2007;48:ARVO E-Abstract 4614.
† Guziewicz KE, et al. IOVS 2011;52:ARVO E-Abstract 4378.
‡ Aguirre GD, et al. IOVS 2016;57:ARVO E-Abstract 2293.
FIGURE 1. Discovery approaches for canine retinal degeneration loci and genes. The cumulative numbers of loci and causative mutations identified
are shown, classified according to the discovery approach used. Note that the chromosomal location and the mutation were reported concurrently
for cd, cord1, osd1, and osd2. *New mutation in a gene for which a mutation is already known. Figure courtesy of Keiko Miyadera.
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promoter validated in proof-of-concept studies differs when
optimized for patients (Supplementary Table S1). Thus the
interplay between vector serotype tropism, promoter, and
model species selected has to be considered before translation
to the clinic is possible.
Promoters
Promoters are traditionally selected to limit transgene expres-
sion to the target cell population and minimize off-target
expression, and are evaluated using reporter genes such as
GFP. Obviously, this is most optimal when the promoter
selected regulates the same therapeutic transgene, although
that is not always possible. Generally, promoters are selected
based on two criteria: (1) The endogenous gene regulated by
the promoter is selectively expressed in the target cell(s); (2)
there is robust expression of a reporter gene in the target cells
when regulated by the chosen promoter. In general, the testing
of target gene specificity and robustness of different AAV
vector serotypes is done in normal retinas, as shown in our
studies,32,43,44 or in vitro45 (Supplementary Table S2).
Although there are a few notable exceptions,46–48 these studies
rarely assess expression of the endogenous gene targeted for
promoter selection at the planned treatment stages, or use the
promoter/reporter gene combination to confirm specific
expression in the affected mutant cells. Thus the direct
application of results obtained in normal retinas to mutants
requires a cautious leap of faith. Indeed, we previously showed
that the human G-coupled receptor kinase 1 (hGRK1)
promoter directed expression of a green fluorescent protein
(GFP) reporter to rods but not cones in normal canine
retinas.43 This observation confirmed earlier studies which
clearly showed that dog cones expressed GRK7, but not
GRK1.49 However, in retinas affected by mutations in
RPGR,50,51 RPGRIP1,52 and NPHP5 (Aguirre GD, et al. IOVS
2016;57:ARVO E-Abstract 2293),53 the hGRK1 promoter
directs expression of the therapeutic transgene to mutant
cones as well as rods, resulting in rescue of function and
structure, even at quite advanced disease stages.
Studies from our lab and others have also shown that
species-specific differences markedly influence the expression
of reporter or therapeutic transgenes (Supplementary Table
S2). In developing a therapeutic strategy for CNGB3 achroma-
topsia, we tested a series of promoters based on the human red
cone opsin locus control region.54 In this dichromatic species
with a single long wavelength–sensitive (L/M-) class of cones
and short wavelength–sensitive S-cones,55 the full-length
promoter, PR2.1, directed GFP expression to all L/M-cones in
normal and CNGB3-mutant retinas48,56 (Fig. 2). In contrast, a
chimeric interphotoreceptor retinoid binding protein/G pro-
tein subunit alpha transducin 2 (IRBP/GNAT2) promoter
expressed GFP in both L/M- and S-cones in the dog (Fig. 2;
Supplementary Table S2). However, when tested in murine and
NHP (Macaca fascicularis) retinas, the PR2.1 promoter
directed GFP expression to the RPE, cones, and rods in the
mouse; expression was present but weak in the NHP L/M-
cones, and the chimeric IRBP/GNAT2 promoter showed no
photoreceptor specificity in NHP retinas.57 The promoter
selected for eventual therapeutic use was the PR1.7 modifica-
tion of the human red cone opsin promoter, which showed
robust GFP expression in L/M- and S-cones in NHP57 as well as
in dogs (Komaromy AM, unpublished observations, 2017).
An equally complex situation exists with cell-specific
promoters targeting rods and cones. In our lab, we chose the
IRBP promoter for RPGR-XLRP gene therapy studies, as it
directed GFP expression specifically to rod and cone photore-
ceptors in normal dog50 and mouse (Lewin AS, unpublished
observations, 2011) retinas (Supplementary Table S2; Fig. 2).
Unfortunately, this promoter was ineffective in directing GFP
expression to foveal or peripheral cones after subretinal
administration in two closely related NHP macaque species
(M. mulatta and M. fascicularis).51 This finding was surprising
given that IRBP expression has been detected in rods and cones
of the human retina by in situ hybridization.58 A possible
explanation for this discrepancy is that the small IRBP promoter
contained only 235 bp of the full-length human IRBP promoter59
and may not have all the regulatory elements needed for cone
expression in NHP retina. It is likely that careful dissection of the
human IRBP promoter will identify sequences that direct
expression to NHP rods and cones. However, such studies
appear less necessary now, as we have found that the hGRK1
promoter is highly effective in directing expression to rods and
both peripheral and central cones in the NHP retina51 (Fig. 2),
and in mutant canine retinas50–53 as well.
Vectors
The most widely used vectors for retinal gene transfer and
therapy have been recombinant AAVs. Each AAV serotype
shows tropism for distinct retinal cells in a species- and
administration route–dependent manner. These vectors are
considered safe and effective, with long-term stability of
expression so that most experimental therapy studies require
only a single vector administration. Their main limitation is
their cargo-carrying capacity, maximal at ~4.7 kb, which
makes them unsuitable for use with full-length, large-sized
genes, for example, CEP290, ABCA4, and others.
Of the vectors used for therapy studies in dogs, AAV2 based,
and to a lesser extent AAV1 and -4, are used for targeting the
RPE, and AAV5, -8, and AAV2tYF for photoreceptors (Supple-
mentary Table S1). However, the vector serotype toolbox is
large, and new versions are continually being developed.60,61
Among the new vectors being developed for dog studies are
those identified by directed evolution using the canine retina.62
Some newer AAV vectors have single or multiple mutations
that replace critical capsid tyrosine residues to enhance
nuclear targeting by bypassing ubiquitination and proteasomal
degradation.63,64 These vector constructs also can be packaged
as self-complementary vectors to avoid delays caused by DNA
synthesis, as must occur to generate double-stranded DNA
from the single-stranded genome of older AAV vectors; but
such modifications further limit their cargo-carrying capacity.65
Self-complementary AAV vectors with capsid modifications
have been evaluated in dogs as a means of increasing
transduction efficiency and onset of gene expression using
GFP reporter or therapeutic genes66 (see below), and are
therapeutically very effective (Aguirre GD, et al. IOVS
2016;57:ARVO E-Abstract 2293).
As with promoters, AAV vector serotype selection for proof-
of-concept and therapeutic applications is complex. Additional-
ly, for translation to the clinic, experience with vector
production protocols by the commercial entity, as well as
intellectual property considerations, often directs serotype
selection. The complexity in vector selection for experimental
studies is illustrated by our own work in dogs using the X-linked
retinal degeneration RPGR-XLRP and NPHP5-LCA models. Both
diseases are characterized by abnormal photoreceptor develop-
ment and early degeneration.36,39,67 We have found that an
AAV5-hIRBP-hRPGRstb vector (Supplementary Table S1) is
effective in arresting the degeneration in RPGR-XLRP when
treatment is initiated at 6 weeks of age, that is, early disease
stage.50 Delaying treatment until the mid and late stages of
disease is equally effective and results in long-term preservation
of structure and function68 (see below). However, when the
same vector/promoter combination with a cNPHP5 therapeutic
transgene is used at the same vector dose in the NPHP5-LCA
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model at 7 weeks of age, the treatment is ineffective; efficacy,
however, is obtained by a 10-fold increase in dose if
administered at 5.7 weeks of age (Aguirre GD, et al. IOVS
2016;57:ARVO E-Abstract 2293). Preliminary studies have
shown that switching the vector/promoter combination from
AAV5-hIRBP- to scAAV8-hGRK1- or scAAV8C&GþT449V-hGRK1-
results in recovery of cone function, and long-term preservation
of structure and function when treatment is initiated at early and
at mid/late stages of disease (Beltran WA and Aguirre GD,
unpublished observations, 2017). These results suggest that for
diseases that are genetically distinct but phenotypically similar,
the vector/promoter used for the experimental studies may have
to be disease specific, and that a hoped-for ‘‘universal’’ vector/
promoter useful for a large class of similar diseases is not
possible at this time. This complicates further translational
applications, at least in the near term, until a sufficient database
resource is obtained from animal studies and human clinical
trials that will inform on vector/promoter selection.
CONCEPTS AND STRATEGIES IN RETINAL GENE
THERAPY
Critically, translating findings from the cage to the bedside
requires careful interpretation of the preclinical data based on
the experimental studies, and a precise determination of how
FIGURE 2. Targeting photoreceptors in the CNGB3/ mutant (A1–A3) and normal (B1–B3) dog retina, and in normal nonhuman primate (NHP, M.
fascicularis; C1–C3) using AAV5 vectors with different promoters. (A1) Four weeks after subretinal injection using PR2.1 promoter, there is robust
native GFP expression (green) in L/M-cones (red), which is the predominant cone class in the canine retina (scale bar: 40 lm). Figure from
Komaromy AM, Alexander JJ, Rowlan JS, et al. Gene therapy rescues cone function in congenital achromatopsia. Hum Mol Genet. 2010;19:2581–
2593.  The Author 2010. Reprinted with permission from Oxford University Press. (A2, A3) The hybrid GNAT2/IRBP promoter results in robust
GFP expression in both L/M- (A2, red) and S- (A3, red) cones (Figs. A2, A3 courtesy of Andra´s Komaromy). (B1–B3) The hIRBP promoter targets
native GFP expression (green) after injection of a 1.53 1011 lg/mL titer. GFP expression is low after 2 weeks (B1), and increases by 8 weeks post
injection (B2); at 8 weeks, hCAR labeling (red) confirms expression in cones (B3). Scale bar: 20 lm. Figures B1–B3 reprinted from Beltran WA,
Cideciyan AV, Lewin AS, et al. Gene therapy rescues photoreceptor blindness in dogs and paves the way for treating human X-linked retinitis
pigmentosa. Proc Natl Acad Sci U S A. 2012;109:2132–2137.  2012 The Authors. (C1–C3) Peripheral retina from NHP after subretinal injection
using hRGK1 promoter to target eGFP (green) expression to rods and cones. hCAR antibody labels cones (red; C1), and colocalizes with eGFP in
cones (C3). White arrows identify the same cone cells in the three images; scale bar: 17 lm. ONL, outer nuclear layer. Figures C1–C3 reprinted with
permission from Beltran WA, Cideciyan AV, Boye SE, et al. Optimization of retinal gene therapy for X-linked retinitis pigmentosa due to RPGR
mutations. Mol Ther. 2017;25:1866–1880.  2017 The American Society of Gene and Cell Therapy.
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closely the model disease parallels the human clinical
phenotype. This information, along with a careful assessment
of the natural history of the patient’s disease, will determine
when to treat, where to treat, how to treat, and how and when
to evaluate the therapeutic outcome. The studies William
Beltran and I have carried out with Samuel G. Jacobson and
Artur V. Cideciyan are a valuable illustration of how model
systems can be maximized to inform on clinical applications.
Examples are studies done in RPE65-LCA,5,23,69 NPHP5-
LCA,39,70 RPGR-XLRP,50,71 and RHO-ADRP.35,72–74 In this
section, I will discuss three issues of relevance to translational
applications.
Is Treatment Forever?
The proof-of-concept studies in both dog and mouse models of
RPE65-LCA by several groups using different AAV vectors and
promoters provided an impetus to finalize all the steps needed
for clinical trials (see Supplementary Table S1). In addition to
the product being safe9,10 and effective, the treatment
outcomes all showed stability of functional rescue, and three
independent clinical trials were initiated and reported in
2008.18–20
The RPE was a very compelling cellular target for gene
therapy, and the RPE65-LCA model is an ideal test bed for the
first venture into this therapeutic modality. Firstly, the RPE is a
homogeneous monolayer with an extensive apical microvillar
network. Administration of vector by subretinal injection
brings the vector into close proximity to the extensive RPE
cellular processes without the need of crossing additional
cellular barriers or the external limiting membrane. Secondly,
AAV2 vectors readily target the RPE cells. Thirdly, tissue-
specific promoters, for example, VMD2 and RPE65, limit
expression to this cell layer, as does the constitutive hybrid
CMV/CBA promoter, at least in the dog.4,44 Of greatest
significance, however, is the dramatic phenotypic change that
occurs within a matter of a few weeks following treatment.
Before therapy, the animal has searching nystagmus, has
incomplete and delayed pupillary responses, and is function-
ally blind with only limited and poor vision at very high
photopic luminances, and the ERG shows absent rod-mediated
responses and absent or very low-amplitude and abnormal
cone signals. Following treatment, all of these clinical signs are
reversed, and functional vision is restored.3,15,75 Thus an
efficacy readout is obtained almost immediately with direct
measurements and without the need for waiting months to
years to assess outcomes, as would be the case in slowly
progressive diseases. Even though the initial studies in the dog
did not assess the stability of the treatment, this was
demonstrated subsequently in longitudinal studies of a subset
of the initially treated dogs and additional animals.3–5
While the proof-of-concept studies in RPE65-LCA dog and
mouse models showed great efficacy, treatment was done
when retinas were primarily dysfunctional with little or no
degeneration. In contrast, the planned clinical trials treated
patients after degeneration had already commenced. Indeed, a
study has shown that of a group of clinically well-characterized
young RPE65-LCA patients (6–17 years) all exhibited abnormal
photoreceptor layer topography, and most had reductions in
foveal and extrafoveal outer nuclear layers.13 This is not
surprising given that the only histopathology assessment of
human retinas with RPE65-LCA showed prenatal degenera-
tion.76
The initial clinical trials indicated that the treatment was
safe and effective in the short term.18–20,77 For example, in one
study patients were followed for up to 36 months, and all
showed improved visual function as measured with full-field
stimulus testing.21 However, long-term observation of the
clinical trial patients in two studies showed continual loss of
photoreceptors,22 which, in treated areas, became comparable
to untreated regions.5,23 Based on the long-term efficacy of
treatment in the dog model, the question arose as to whether
the discrepant results between man and model result from a
unique susceptibility of the human retina associated with the
disease or its treatment, or if efficacy depends on the extent of
degeneration at the time of treatment.
We have examined this question in a cohort of mutant dogs
treated unilaterally at the stage of disease when only
dysfunction is present (ages: 0.3–2.4 years), and followed
noninvasively by ERG and optical coherence tomography
(OCT) and terminally by histopathology (ages: 6.9–11.2 years).
In parallel, a second cohort of unilaterally treated dogs was
examined noninvasively by OCT and ERG after treatment at the
dysfunction/degeneration stage of disease (ages: 4.9–6.6
years).5 Early-treated dogs show recovery of rod and cone
function that is sustained and preservation of outer nuclear
layer integrity in the treated regions, both by OCT and by
histopathology; the treated areas show RPE65 expression and
preservation of rod outer segments5 (Figs. 3IA–D, 3IIA1-5, 3III).
The late-treated dogs show recovery of rod and cone ERG
function in the treated eyes, an indication that the therapy was
successful, but noninvasive assessment of outer nuclear layer
(ONL) structure showed degeneration that is comparable to
that untreated regions5 (Figs. 3ID, 3IIB1-5). This is similar to the
situation occurring in patients treated at the dysfunction/
degeneration stage of disease.
The reason(s) for the short-lived positive treatment effect in
patients, and in dogs treated at the dysfunction/degeneration
stage of disease, is unknown. One group posits that their
vector had insufficient potency to provide the required RPE65
enzymatic activity needed for long-term sustained gains in
function and preservation of structure. Consequently an
optimized AAV5-OPTIRPE65 vector has been developed that
reportedly has 300-fold or greater RPE65 enzymatic activity,78
and now is in clinical trials (NCT02781480) in the United
Kingdom. A second group has proposed that the ongoing
degeneration in the presence of rescued function emphasizes
the need for combinatorial therapies that combine one of
several neuroprotective, antiapoptotic, or other agent(s) as
adjunct to the specific gene augmentation therapy,5 and these
studies are ongoing. Yet another group questions the findings
of the latter study,79 but have not provided details yet that the
cohort of patients treated in their initial clinical trial fail to
show progressive degeneration and dysfunction when mea-
sured with the same quantitative retinal structure and visual
function methods used in the other two trials.18 What is clear is
that in at least two clinical trials, progressive degeneration
continues in spite of initial positive treatment effects. The
ongoing studies to determine the cause and prevention of this
unanticipated finding will be important for managing patients
with this disease after treatments are commercialized, as well
as informing on the basic biology of retinal diseases in general
and the development of future treatments.
What Happens When Treatment Is a Success but
the Patient Is Blind: CNTF-Mediated Photoreceptor
Deconstruction in CNGB3 Achromatopsia
Two mutations in canine CNGB3 result in very severe loss of
cone ERG function and photopic vision. These mutations, a
~500-kb genomic deletion and a missense change, result in an
identical clinical phenotype.33 The disease locus name, cd for
cone degeneration, was based on the marked decrease in the
number of cones at very late stages of the disease, but does not
truly reflect the status of the cone photoreceptor mosaic in the
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first 3 to 4 years of life. Affected dogs have small, abnormal
cone ERG responses until ~8 to 10 weeks of age, which then
disappear. The absence of cone function persists for the rest of
the dog’s life. Presumably, the presence of intact cyclic
nucleotide gated channel alpha 3 (CNGA3) protein in these
mutant retinas allows for transient formation of functional
CNGA3 homotetramer channels, and cone function, albeit
abnormal, is present early during development.48,80
Subretinal injections of a therapeutic transgene (AAV5-
PR2.1-hCNGB3) restored ERG cone function and photopic
vision in CNGB3 mutants regardless of the mutation class.
Long-term assessment in a subset of treated dogs showed that
cone flicker was preserved stably for more than 2.5 years
following treatment48 (Komaromy AM and Aguirre GD,
unpublished observations, 2017; Figs. 4A, 4B). Recovery of
cone function following gene therapy was accompanied by the
restoration of normal cone phototransduction protein locali-
zation to the cone outer segments in treated regions.
Specifically, while the cone phototransduction proteins,
GNAT2 and CNGA3, were mislocalized from the outer segment
to elsewhere in the cone cell in the untreated mutant retinas,
hCNGB3 augmentation resulted in the proper localization of
these proteins in the L/M-cone outer segments48 (Fig. 4E).
These initial studies established treatment efficacy, and, in
concordance with the promoter assessment56 (Supplementa-
ry Table S2), confirmed that the PR2.1 promoter was the most
FIGURE 3. I. Long-term efficacy of rescued rod and cone retinal function in RPE65 mutants treated at an early disease stage and evaluated up to a
decade later (A–D), or treated late and evaluated 1 month after the treatment (E). (A) Dark-adapted (DA) ERGs evoked by standard white flashes
(black traces), or under light-adapted (LA) (red traces) conditions. Black vertical lines show the timing of the flashes. (B) ERG photoresponses
evoked by white flashes of high energy under dark-adapted conditions; same data are shown on slow (upper) and fast (lower) time scales. Gray
lines show the baseline and the 4-ms time point where rod photoreceptor responses were measured. (C) Comparison of rod and cone function in
the treated RPE65-mutant dogs (Tx; green triangles) compared with previously published4 normal (N) and untreated control (Ctrl) eyes. Rod
function shown refers to the DA ERG photoresponse amplitude at 4 ms, and cone function refers to the peak amplitude of the LA 29-Hz waveform.
Horizontal dashed lines represent the upper limit (mean þ 3 SD) of the respective measurement in the group of untreated control eyes. (D)
Durability of the rod and cone ERG amplitudes in dog D23 treated a decade earlier. Subretinally treated right eye is shown with green symbols, and
the intravitreally treated left eye is shown with gray symbols. Lines show previously published data extending to age 3 years.4 (E) Bilateral ERGs
recorded with similar methods and stimuli as shown in (A) in a normal dog and three unilaterally treated older RPE65-mutant dogs (age range from
4.9 to 6.6 years). ERG recordings performed 1 month later show definite treatment effects in the eyes with gene therapy. II. Gene therapy outcomes
in RPE65-mutant dogs treated before (A1–A5) and after (B1–B5) the onset of retinal degeneration. (A1, A2) Photoreceptor (ONL) thickness
topography in two dogs treated before the onset of the degeneration and evaluated ~5 to 9 years later. There is retention of ONL thickness within
the treatment region (dashed lines). (A3–A5) ONL thickness quantified as a function of age at five retinal locations in five dogs treated before the
initiation of degeneration. Red symbols correspond to retinal locations outside the treatment region, and green symbols correspond to locations
within the treatment region. (B1, B2) ONL thickness topography in two dogs treated after the onset of degeneration. There is no evidence for
thicker ONL within the treatment regions compared with outside the treatment regions. (B3–B5) ONL thickness quantified as a function of age at
five retinal locations in treated eyes. Both untreated control (red symbols) and treated (green symbols) regions are not substantially different
compared with the natural history of disease. III. Retina of dog D23 treated at 0.3 year before the onset of retinal degeneration shows remarkable
rescue of photoreceptors from degeneration when assessed over a decade later. (A) Schematic representation of the en face image showing the
treatment area (dashed lines), on which is superimposed the ONL rows (mean of three values in each area sampled) and disease staging (a,
advanced atrophy with gliosis and loss of retinal layer organization; m, moderate photoreceptor loss with 1/3 to 1/2 of ONL remaining; n, normal)
assessed at 11.2 years. (B–D) Representative images taken from areas identified in (A). In the treatment area, there is normal retinal preservation (B),
although the RPE shows vacuolated inclusions typical of the disease (arrowheads). At the edge of the treatment border (C), the photoreceptor layer
becomes markedly attenuated and is absent (D) outside of the treatment region. Double immunolabeling with RPE65 (red) and rod opsin (green)
taken from region corresponding to (B). RPE labeling: RPE is present inside the treatment region, and rod outer segment labeling is distinct. RPE,
retinal pigment epithelium; GCL, ganglion cell layer; NFL, nerve fiber layer; OPL, outer plexiform layer; OS/IS, outer and inner segment layer; INL,
inner nuclear layer; IPL, inner plexiform layer; scale bar: 20 lm. Figures and legends modified from Cideciyan AV, Jacobson SG, Beltran WA, et al.
Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc Natl
Acad Sci U S A. 2013;110:E517–E525.  2013 The Authors.
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effective in producing a sustained recovery of cone function.
The shorter versions of the human red cone opsin promoter,
PR0.5 and 3LCR-PR0.5, were not effective in treating young
animals; and recovery of cone function either did not occur or
was transient, and hCNGB3 transgene expression, in general,
was low48 (Fig. 4C). However, studies using the AAV5-PR2.1-
hCNGB3 therapeutic vector did reveal an apparent age-
dependent effect in the rescue of cone function. While 11 of
14 eyes recovered cone function when treated at less than 0.5
years of age, only 1 of 3 did so when treatment was initiated
after 1 year of age. This absence of functional rescue was not
due to cone loss in older retinas as cone loss is gradual, and at
1 year of age the superior central region of the retina, the
region targeted for therapy, still retains ~80% and 97%,
respectively, of the L/M- and S-cone numbers when compared
to control.81 Similarly, treatment failure was not due to
inefficient targeting of mutant cones, as hCNGB3 mRNA
expression in the ‘‘nonrescued’’ retinas was comparable to or
only slightly lower than in successfully treated eyes (Fig. 4C).
In addition, untreated mutant retinas had levels of cone gene
expression (CNGA3, CNGB3 [present only in missense
mutants], L/M- and S-cone opsins) that were comparable to
wild type, an indication that the principal components
underlying cone function are not compromised.48 Based on
these findings, we posited that treatment failure in these eyes
resulted from the inability of the structurally stable mutant
cone outer segment to assemble functional CNG channels,
despite the expression of both channel subunits after
treatment. We further reasoned that if cones could reform
an outer segment at the time of treatment, functional
channels would be assembled. Such an approach would have
required the transient elimination of the cone outer segment
structure without permanently impairing their long-term
viability and function. This effect can be mediated by ciliary
neurotrophic factor (CNTF), and we have used it as a
therapeutic adjunct to gene therapy.81
Intravitreal injection of CNTF in the rat retina leads to a
marked shortening of the photoreceptor outer segments and
decrease in photoreceptor gene expression; maximal effects
occur within 3 to 6 days after injection, and are fully reversible
within 3 weeks.82 Similarly, intravitreal CNTF in the normal
dog retina has a maximal effect by 1 week in terms of
decreased rod and cone ERG amplitudes, shortening of rod, S-
and L/M-cone outer segments, and rod and cone gene
expression. By 5 weeks after treatment the retina returns to
normal. As the changes are reversible and photoreceptors
transiently become more immature immediately following
CNTF, we have termed this process transient photoreceptor
deconstruction.81 Although the effects are panretinal and
affect rods and cones equally, for the purpose of the CNGB3
gene therapy work, the cell of interest for the effect is the
cone.
To determine if CNTF-mediated transient photoreceptor
deconstruction would enhance cone functional rescue in older
CNGB3 mutant retinas, we injected eyes from older (age range,
1.2–3.5 years) mutant dogs with either 30 lL CNTF (~4–5 lg/
mL vitreous) or PBS 7 days prior to a subretinal injection of
AAV5-PR2.1-hCNGB3. Significantly, all seven mutant eyes
pretreated with CNTF had sustained recovery of cone function
following hCNGB3 gene augmentation, an effect that was not
found in any of the seven eyes pretreated with PBS81 (Table 2).
Quantitative RT-PCR assessment of hCNGB3 therapeutic
transgene levels indicated comparable expression levels
between PBS- and CNTF-pretreated retinas (Fig. 4D). However,
only the CNTF-pretreated retinas showed the proper localiza-
tion of GNAT2 and CNGA3, two cone phototransduction
proteins required for normal function, in the L/M-cone outer
segments (Fig. 4E); as a specific CNGB3 antibody was not
available, the expression of this critical protein and its
localization could not be determined.
The achromatopsia gene therapy studies in the canine
model raise important translational issues. First, will patients
have cones present at the age of treatment? Recent studies
combining high-resolution OCT and adaptive optics scanning
light ophthalmoscopy have shown that while patients have
lower than normal numbers of foveal cones, those remaining
likely provide suitable therapeutic targets for gene augmenta-
tion.83 Furthermore, a 6- to 26-month short-term longitudinal
study of CNGB3-achromatopsia patients reported that the
fovea remained structurally stable.83 Secondly, it is still an open
question whether the need for CNTF-mediated photoreceptor
deconstruction at later stages of the disease is a canine-specific
effect or may be required as an adjunct to gene augmentation
in human patients. In studies of gene augmentation in sheep
with CNGA3-achromatopsia, successful cone functional rescue
resulted regardless of the animal’s age at the time of
treatment.84 This difference can possibly be explained by the
ability of CNGA3, but not CNGB3 subunits, to form functional
channels on their own.80
The issue of pretreatment with CNTF prior to CNGB3
augmentation in ongoing clinical trials is not possible or
practical, due in part to regulatory issues, but also because one
cannot predict a priori which patients, if any, will require such
treatment. Pretreatment, however, may not be necessary, as
preliminary studies have shown that intravitreal CNTF
administered after unsuccessful gene therapy rescues cone
function in the mutant dog, and CNTF-Encapsulated Cell
Therapy devices are able to effectively deconstruct cone
photoreceptors in mutant dogs (Komaromy AM, unpublished
observations, 2013). The CNTF ECT device (NT-501 ECT) from
TABLE 2. Cone Function Rescue in CNGB3 Mutants After Gene Augmentation Therapy; Effect of Age and Treatment With CNTF Prior to Gene
Therapy With AAV5-PR2.1-hCNGB3
Studies No. Eyes Age, y
CNGB3 Genotype Sustained Cone Function Rescue
CNGB3/ CNGB3m/m Yes No
Study 148
Vector 14 0.54 11 3 11 3, CNGB3/
Vector 3 ‡1 0 3 1 2
Study 281
CNTFþvector 7 1.2–3.5 4 3 7 0
PBSþvector 7 1.2–3.5 4 3 0 7
Eyes treated with intravitreal CNTF (12 lg in 30 lL PBS) or PBS (30 lL) 1 week prior to subretinal injection of AAV5-PR2.1-hCNGB3 (injection
volumes 140–200 lL; dose¼ 7.963 1011–4.023 1013 vg/ml; the same vector dose was used in pairs of eyes pretreated with intravitreal CNTF or
PBS). For additional details, see Table 1 in Ref. 81.
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FIGURE 4. Gene therapy outcomes in CNGB3-achromatopsia. (A) CNGB3 mutants with either a missense mutation (m/m) or genomic deletion (/)
show normal rod ERG responses, but absent cone responses. Gene therapy restores the cone ERG responses (far right column), and the effect is
sustained for at least 2.5 years (B). (C) Cone ERG flicker amplitude increased with higher hCNGB3 transgene expression. Dogs with no recovery of
cone function had low levels of transgene expression and were treated with the less robust 3LCR-PR0.5 promoter (red circle, treatment age 8, 23, 28
weeks; green circle, treatment age 60–81 weeks). The optimal PR2.1 promoter resulted in high levels of transgene expression in one dog (blue
circle), but no cone function rescue when treatment was done at 54 weeks. Figures 4A–C reprinted from Komaromy AM, Alexander JJ, Rowlan JS, et
al. Gene therapy rescues cone function in congenital achromatopsia. Hum Mol Genet. 2010;19:2581–2593.  2010 The Author. Reprinted with
permission from Oxford University Press. (D) Photoreceptor deconstruction with CNTF. The relative amounts of retinal hCNGB3 mRNA expression
were comparable and not significantly different when subretinal AAV injections were preceded by either intravitreal PBS (no cone function
recovery) or CNTF (cone function recovery). (E) In the wild-type retina, CNGA3 and GNAT2 colocalize with L/M opsin in the cone outer segment
(top). Gene therapy following intravitreal PBS (middle) fails to correct the mislocalization of CNGA3 and GNAT2 from the outer segment (middle).
However, pretreatment with CNTF 1 week prior to gene therapy corrects the mislocalization in the now functional L/M cones (middle). Scale bar:
10 lm. Figures 4D, 4E reprinted with permission from Komaromy AM, Rowlan JS, Corr AT, et al. Transient photoreceptor deconstruction by CNTF
enhances rAAV-mediated cone functional rescue in late stage CNGB3-achromatopsia. Mol Ther. 2013;21:1131–1141.  2013 The American Society
of Gene & Cell Therapy.
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Neurotech (Cumberland, RI, USA) is commercially available
and approved for the treatment of macular telangiectasia.
Developing Treatments at Patient-Relevant Disease
Stages
Proof-of-principle studies optimize successful outcomes by
using animals prior to or during the early disease stages to
eliminate confounding disease variables, and determine the
optimal vector, promoter, transgene, and dose needed for
effective therapy. If treatment fails under these ideal condi-
tions, further preclinical and clinical development of the
therapy usually is not warranted unless alternative data from
other model systems, for example, cell culture, human induced
pluripotent stem cells (IPS cells), are available. Once treatment
success is established, optimizing the treatment at patient-
relevant disease stages is critical to inform and direct the
translational studies that develop the actual treatments. It is at
this stage that treatments often fail, either because the model
does not recapitulate the essential features of the human
FIGURE 5. I. Retinal disease phenotypes caused by RPGR-ORF15 mutations in human patients and in dogs. (A) Different patterns of photoreceptor
topography in two XLRP patients with RPGR mutations. ONL thickness topography is mapped to a pseudocolor scale. (Inset) Representative normal
subject. Locations of fovea and optic nerve (ON) are shown. (B) Different patterns of photoreceptor topography in the canine models of RPGR-
ORF15; mapping as performed with the human data. (Inset) Map of a representative wild-type dog with location of ON labeled. (C) ONL thickness
profile along the vertical meridian (Inset) comparing XLPRA1 and XLPRA2 of different ages (thin traces) versus normal results (gray band). Mean
(6SD) results are from groups of younger (7–28 weeks) and older (36–76 weeks) dogs. The thicker red line represents the data from the oldest dogs
examined (>144 weeks old). Brackets mark the location of the high photoreceptor density corresponding to the canine visual streak. Figures and
legends in I modified from Beltran WA, Cideciyan AV, Lewin AS, et al. Gene therapy rescues photoreceptor blindness in dogs and paves the way for
treating human X-linked retinitis pigmentosa. Proc Natl Acad Sci U S A. 2012;109:2132–2137.  2012 The Authors. II, III. Efficacy and long-term
stability of gene therapy intervention at (II) mid-stage and (III) late-stage disease. (A) Pseudocolor maps of ONL thickness topography in XLPRA2
dogs treated at 12 (mid-stage) and 26 (late-stage) weeks of age. Dashed outline is the retinal region corresponding to the subretinal vector bleb at
treatment. Schematic, right, paired loci across the treatment boundary and in the inferior retina chosen for quantitative evaluation. Eyes are shown
as equivalent right eyes with optic nerve and major blood vessels overlaid for ease of comparability. T, temporal; N, nasal retina. (B) Progressive
changes in ONL fraction recorded serially between 11 (mid-stage) and 25 (late-stage) weeks through to 130 weeks of age in treated (green) and
untreated (red) loci in the superior and inferior retinas of three XLPRA2 dogs treated for each disease stage. None of the three late-stage treated eyes
received injection in the inferior retina; thus, only untreated loci are shown in inferior retina. Vertical green arrows depict the timing of treatment.
Dashed lines show the range of ONL fraction expected in wild-type eyes or natural history of progression in untreated XLPRA2 eyes. Smaller
symbols represent the individual data and larger symbols with error bars represent mean 6 SD; *P < 0.01 for paired t-tests between treated and
untreated loci. (C) Retinal morphology at 113 weeks of age in the untreated (UnTx) and treated (Tx) areas of a dog injected at mid- and late-stage
disease and immunohistochemistry labeling of stable human RPGR transgene product, which is present only in treated areas. IV. Long-term
durability of retinal function after gene therapy intervention at late-stage disease. Representative ERG traces of rod and mixed rod–cone responses
recorded dark-adapted and cone responses to single stimuli, or 29-Hz cone flicker recorded light-adapted. Figures and legends in II, III, and IV
modified from Beltran WA, Cideciyan AV, Iwabe S, et al. Successful arrest of photoreceptor and vision loss expands the therapeutic window of retinal
gene therapy to later stages of disease. Proc Natl Acad Sci U S A. 2015;112:E5844–E5853.  2015 The Authors.
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disease, or because the disease is so aggressive and rapidly
progressive that treatments are not effective. The lack of
sustained efficacy in the initial RPE65-LCA clinical trials serves
as an important lesson5,22,23 to emphasize that translation to
the clinic following successful proof-of-concept results3 should
be based on studies in which efficacious treatments are done at
the patient-relevant disease stages, and in which detailed
information is generated a priori on the natural history of the
disease in the model and man. Such information will determine
when to treat, where to treat, how to treat, and how and when
to evaluate the therapeutic outcomes.85 The RPGR-XLRP
studies in the canine model illustrate this optimal approach.
In the dog, two naturally occurring distinct microdeletions
in ORF15 result in different disease phenotypes referred to as
X-linked progressive retinal atrophy 1 (XLPRA1; del 1028-1032)
and XLPRA2 (del 1084-1085). XLPRA1 is juvenile but
postdevelopmental in onset, and progresses over several years;
XLPRA2 is early onset and rapidly progressive.36 Both models
correspond to the disease spectrum of human X-linked retinitis
pigmentosa (XLRP), and, although differing in relative severity,
they would be equivalent to human disease occurring within
the first decade of life. XLPRA1, as in many RPGR-XLRP
patients, shows dramatic photoreceptor loss peripherally, with
relatively greater retention of ONL thickness at and near the
central visual streak region. In contrast, XLPRA2 is character-
ized by loss of central photoreceptors and diseased, yet better
preserved, peripheral photoreceptors50 (Figs. 5IA–5IC).
Based on the disease topography in the XLPRA2 model, we
directed treatments to the superior nasal quadrant to avoid
issues concerning greater central versus peripheral loss of
photoreceptors.50 Gene augmentation with AAV5-hIRBP-
hRPGR vectors showed that XLPRA1 disease was prevented
when treatment was initiated in the predegenerate stage
(treatment: 28 weeks; termination: 77 weeks), when photore-
ceptor structure and function remained normal. Treatment of
XLPRA2 retinas at 5 weeks, just before the peak of cell death,67
showed rescue of rod and cone function along with structural
preservation of photoreceptors and ONL by 33 weeks of age.
At this age, the bipolar dendritic arbors had reformed and inner
retinal remodeling was abrogated in treated areas.50 Treatment
at this age shows ~3 year stability of rescued rod and cone
function, vision, and structure.68
To determine if treatment is still successful if delayed until
more advanced disease stages, we carried out studies in older
animals. Two disease stages were selected as these represent
intermediate time points in the degenerative process that are
representative of disease stages in the patient population. At
the mid-stage and late-stage disease, the mutant retina had lost
~40% and 60% of the photoreceptors and corresponding ONL.
Unilateral treatment of affected dogs showed a remarkable
arrest of further disease progression. This could be monitored
over time noninvasively by mapping ONL topography, and by
objectively assessing ERG function and vision using an
obstacle-avoidance course and a forced two-choice Y maze
(Figs. 5IIA–5IIC; 5IIIA–C, 5IV). Not only was the treatment
successful, but it also was stable, and there was no further
progression in disease over the 2.5þ years of posttreatment
assessment.68 Such efficacy and stability, regardless of the
disease stage at the time of treatment, holds promise for
forthcoming clinical trials.
SUMMARY
Gene therapy as a therapeutic modality for treating previously
incurable forms of retinal blindness is making great advances
since the successful proof-of-concept studies of canine RPE65-
LCA in 2001.3 The field is still young, but the excitement in
both the scientific community and patient advocacy groups has
been energizing. I feel fortunate to be part of this therapeutic
adventure, and to have collaborated with superb colleagues
who continually make this work enjoyable and exciting. Of
equal importance, I am proud to have conveyed to the
scientific community the importance of the canine model of
inherited retinal degeneration as a model for disease gene
discovery, for investigating molecular mechanisms of disease,
and, most important, for developing therapies to treat human
and canine retinal blindness. Such studies truly confirm that
dogs are man’s best friend.
Acknowledgments
The author thanks William A. Beltran, Leslie B. King, and Samuel G.
Jacobson for critical review of the manuscript and many helpful
comments. The author also thanks the scientific collaborators,
postdoctoral fellows, graduate students, and technical and support
staff whose contributions have been critically important to these
studies.
Supported by grants from National Institutes of Health (EY-06855,
17549, 19304, P30EY14801, R24EY022012; the author alone is
responsible for the content and writing of the paper, and the
content does not necessarily represent the official views of the
National Eye Institute or the National Institutes of Health), the
Foundation Fighting Blindness (Center and Individual Investigator
grants), an Alcon Research Foundation Award, and the Van Sloun
Fund for Canine Genetic Research.
Disclosure: G.D. Aguirre, P
References
1. Bramall AN, Wright AF, Jacobson SG, McInnes RR. The
genomic, biochemical, and cellular responses of the retina
in inherited photoreceptor degenerations and prospects for
the treatment of these disorders. Annu Rev Neurosci. 2010;
33:441–472.
2. Wright AF, Chakarova CF, Abd El-Aziz MM, Bhattacharya SS.
Photoreceptor degeneration: genetic and mechanistic dissec-
tion of a complex trait. Nat Rev Genet. 2010;11:273–284.
3. Acland GM, Aguirre GD, Ray J, et al. Gene therapy restores
vision in a canine model of childhood blindness. Nat Genet.
2001;28:92–95.
4. Acland GM, Aguirre GD, Bennett J, et al. Long-term restoration
of rod and cone vision by single dose rAAV-mediated gene
transfer to the retina in a canine model of childhood
blindness. Mol Ther. 2005;12:1072–1082.
5. Cideciyan AV, Jacobson SG, Beltran WA, et al. Human retinal
gene therapy for Leber congenital amaurosis shows advancing
retinal degeneration despite enduring visual improvement.
Proc Natl Acad Sci U S A. 2013;110:E517–E525.
6. Narfstrom K, Katz ML, Bragadottir R, et al. Functional and
structural recovery of the retina after gene therapy in the
RPE65 null mutation dog. Invest Ophthalmol Vis Sci. 2003;
44:1663–1672.
7. Rakoczy PE, Lai CM, Yu MJ, et al. Assessment of rAAV-
mediated gene therapy in the Rpe65/ mouse. Adv Exp Med
Biol. 2003;533:431–438.
8. Roman AJ, Boye SL, Aleman TS, et al. Electroretinographic
analyses of Rpe65-mutant rd12 mice: developing an in vivo
bioassay for human gene therapy trials of Leber congenital
amaurosis. Mol Vis. 2007;13:1701–1710.
9. Jacobson SG, Acland GM, Aguirre GD, et al. Safety of
recombinant adeno-associated virus type 2-RPE65 vector
delivered by ocular subretinal injection. Mol Ther. 2006;13:
1074–1084.
Retinal Gene Therapy IOVS j October 2017 j Vol. 58 j No. 12 j 5408
10. Jacobson SG, Boye SL, Aleman TS, et al. Safety in nonhuman
primates of ocular AAV2-RPE65, a candidate treatment for
blindness in Leber congenital amaurosis. Hum Gene Ther.
2006;17:845–858.
11. Jacobson SG, Aleman TS, Cideciyan AV, et al. Human cone
photoreceptor dependence on RPE65 isomerase. Proc Natl
Acad Sci U S A. 2007;104:15123–15128.
12. Jacobson SG, Aleman TS, Cideciyan AV, et al. Identifying
photoreceptors in blind eyes caused by RPE65 mutations:
prerequisite for human gene therapy success. Proc Natl Acad
Sci U S A. 2005;102:6177–6182.
13. Jacobson SG, Cideciyan AV, Aleman TS, et al. Photoreceptor
layer topography in children with leber congenital amaurosis
caused by RPE65 mutations. Invest Ophthalmol Vis Sci. 2008;
49:4573–4577.
14. Jacobson SG, Aleman TS, Cideciyan AV, et al. Defining the
residual vision in leber congenital amaurosis caused by RPE65
mutations. Invest Ophthalmol Vis Sci. 2009;50:2368–2375.
15. Aguirre GK, Komaromy AM, Cideciyan AV, et al. Canine and
human visual cortex intact and responsive despite early
retinal blindness from RPE65 mutation. PLoS Med. 2007;4:
e230.
16. Roman AJ, Cideciyan AV, Aleman TS, Jacobson SG. Full-field
stimulus testing (FST) to quantify visual perception in
severely blind candidates for treatment trials. Physiol Meas.
2007;28:N51–N56.
17. Roman AJ, Schwartz SB, Aleman TS, et al. Quantifying rod
photoreceptor-mediated vision in retinal degenerations: dark-
adapted thresholds as outcome measures. Exp Eye Res. 2005;
80:259–272.
18. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of
gene transfer for Leber’s congenital amaurosis. N Engl J Med.
2008;358:2240–2248.
19. Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene
therapy on visual function in Leber’s congenital amaurosis. N
Engl J Med. 2008;358:2231–2239.
20. Hauswirth W, Aleman TS, Kaushal S, et al. Treatment of leber
congenital amaurosis due to RPE65 mutations by ocular
subretinal injection of adeno-associated virus gene vector:
short-term results of a phase I trial. Hum Gene Ther. 2008;19:
979–990.
21. Jacobson SG, Cideciyan AV, Ratnakaram R, et al. Gene therapy
for leber congenital amaurosis caused by RPE65 mutations:
safety and efficacy in 15 children and adults followed up to 3
years. Arch Ophthalmol. 2012;130:9–24.
22. Bainbridge JW, Mehat MS, Sundaram V, et al. Long-term effect
of gene therapy on Leber’s congenital amaurosis. N Engl J
Med. 2015;372:1887–1897.
23. Jacobson SG, Cideciyan AV, Roman AJ, et al. Improvement and
decline in vision with gene therapy in childhood blindness. N
Engl J Med. 2015;372:1920–1926.
24. Bonini NM, Fortini ME. Applications of the Drosophila retina
to human disease modeling. Results Probl Cell Differ. 2002;
37:257–275.
25. Michot P, Chahory S, Marete A, et al. A reverse genetic
approach identifies an ancestral frameshift mutation in RP1
causing recessive progressive retinal degeneration in Europe-
an cattle breeds. Genet Sel Evol. 2016;48:56.
26. Bellone RR, Holl H, Setaluri V, et al. Evidence for a retroviral
insertion in TRPM1 as the cause of congenital stationary night
blindness and leopard complex spotting in the horse. PLoS
One. 2013;8:e78280.
27. Aguirre GD, Acland GM. Models, mutants and man: searching
for unique phenotypes and genes in the dog model of
inherited retinal degeneration. In: Ostrander EA, Giger U,
Lindblad-Toh K, eds. The Dog and Its Genome. Cold Spring
Harbor, NY: Cold Spring Harbor Laboratory Press; 2006:291–
325.
28. Miyadera K, Acland GM, Aguirre GD. Genetic and phenotypic
variations of inherited retinal diseases in dogs: the power of
within- and across-breed studies. Mamm Genome. 2012;23:
40–61.
29. Aguirre GD, Baldwin V, Pearce-Kelling S, Narfstrom K, Ray K,
Acland GM. Congenital stationary night blindness in the dog:
common mutation in the RPE65 gene indicates founder
effect. Mol Vis. 1998;4:23–29.
30. Guziewicz KE, Sinha D, Gomez NM, et al. Bestrophinopathy:
an RPE-photoreceptor interface disease. Prog Retin Eye Res.
2017;58:70–88.
31. Guziewicz KE, Zangerl B, Lindauer SJ, et al. Bestrophin gene
mutations cause canine multifocal retinopathy: a novel animal
model for Best disease. Invest Ophthalmol Vis Sci. 2007;48:
1959–1967.
32. Beltran WA, Cideciyan AV, Guziewicz KE, et al. Canine retina
has a primate fovea-like bouquet of cone photoreceptors
which is affected by inherited macular degenerations. PLoS
One. 2014;9:e90390.
33. Sidjanin DJ, Lowe JK, McElwee JL, et al. Canine CNGB3
mutations establish cone degeneration as orthologous to the
human achromatopsia locus ACHM3. Hum Mol Genet. 2002;
11:1823–1833.
34. Tanaka N, Dutrow EV, Miyadera K, et al. Canine CNGA3 gene
mutations provide novel insights into human achromatopsia-
associated channelopathies and treatment. PLoS One. 2015;
10:e0138943.
35. Kijas JW, Cideciyan AV, Aleman TS, et al. Naturally occurring
rhodopsin mutation in the dog causes retinal dysfunction and
degeneration mimicking human dominant retinitis pigmento-
sa. Proc Natl Acad Sci U S A. 2002;99:6328–6333.
36. Zhang Q, Acland GM, Wu WX, et al. Different RPGR exon
ORF15 mutations in Canids provide insights into photorecep-
tor cell degeneration. Hum Mol Genet. 2002;11:993–1003.
37. Aguirre GD, Yashar BM, John SK, et al. Retinal histopathology
of an XLRP carrier with a mutation in the RPGR exon ORF15.
Exp Eye Res. 2002;75:431–443.
38. Beltran WA, Acland GM, Aguirre GD. Age-dependent disease
expression determines remodeling of the retinal mosaic in
carriers of RPGR exon ORF15 mutations. Invest Ophthalmol
Vis Sci. 2009;50:3985–3995.
39. Downs LM, Scott EM, Cideciyan AV, et al. Overlap of abnormal
photoreceptor development and progressive degeneration in
Leber congenital amaurosis caused by NPHP5 mutation. Hum
Mol Genet. 2016;25:4211–4226.
40. Mutti DO, Zadnik K, Murphy CJ. Naturally occurring vitreous
chamber-based myopia in the Labrador retriever. Invest
Ophthalmol Vis Sci. 1999;40:1577–1584.
41. Tao W, Wen R, Goddard MB, et al. Encapsulated cell-based
delivery of CNTF reduces photoreceptor degeneration in
animal models of retinitis pigmentosa. Invest Ophthalmol Vis
Sci. 2002;43:3292–3298.
42. Gu¨ven D, Weiland JD, Fujii G, et al. Long-term stimulation by
active epiretinal implants in normal and RCD1 dogs. J Neural
Eng. 2005;2:S65–S73.
43. Beltran WA, Boye SL, Boye SE, et al. rAAV2/5 gene-targeting to
rods: dose-dependent efficiency and complications associated
with different promoters. Gene Ther. 2010;17:1162–1174.
44. Guziewicz KE, Zangerl B, Komaromy AM, et al. Recombinant
AAV-mediated BEST1 transfer to the retinal pigment epithe-
lium: analysis of serotype-dependent retinal effects. PLoS
One. 2013;8:e75666.
45. Nicoud M, Kong J, Iqball S, et al. Development of photore-
ceptor-specific promoters and their utility to investigate EIAV
Retinal Gene Therapy IOVS j October 2017 j Vol. 58 j No. 12 j 5409
lentiviral vector mediated gene transfer to photoreceptors. J
Gene Med. 2007;9:1015–1023.
46. Alexander JJ, Umino Y, Everhart D, et al. Restoration of cone
vision in a mouse model of achromatopsia. Nat Med. 2007;13:
685–687.
47. Busskamp V, Duebel J, Balya D, et al. Genetic reactivation of
cone photoreceptors restores visual responses in retinitis
pigmentosa. Science. 2010;329:413–417.
48. Komaromy AM, Alexander JJ, Rowlan JS, et al. Gene therapy
rescues cone function in congenital achromatopsia. Hum Mol
Genet. 2010;19:2581–2593.
49. Weiss ER, Ducceschi MH, Horner TJ, Li A, Craft CM, Osawa S.
Species-specific differences in expression of G-protein-cou-
pled receptor kinase (GRK) 7 and GRK1 in mammalian cone
photoreceptor cells: implications for cone cell phototrans-
duction. J Neurosci. 2001;21:9175–9184.
50. Beltran WA, Cideciyan AV, Lewin AS, et al. Gene therapy
rescues photoreceptor blindness in dogs and paves the way
for treating human X-linked retinitis pigmentosa. Proc Natl
Acad Sci U S A. 2012;109:2132–2137.
51. Beltran WA, Cideciyan AV, Boye SE, et al. Optimization of
retinal gene therapy for X-linked retinitis pigmentosa due to
RPGR mutations. Mol Ther. 2017;25:1866–1880.
52. Lheriteau E, Petit L, Weber M, et al. Successful gene therapy in
the RPGRIP1-deficient dog: a large model of cone-rod
dystrophy. Mol Ther. 2013;22:265–277.
53. Aguirre GA. Going beyond the connecting cilium: cone outer
segment formation after NPHP5 gene therapy. Fourth Annual
Innovation Summit: Retinal Cell and Gene Therapy. Balti-
more, Maryland, United States, May 2017.
54. Wang Y, Macke JP, Merbs SL, et al. A locus control region
adjacent to the human red and green visual pigment genes.
Neuron. 1992;9:429–440.
55. Neitz J, Geist T, Jacobs G. Color vision in the dog. Vis
Neurosci. 1989;3:119–125.
56. Komaromy AM, Alexander JJ, Cooper AE, et al. Targeting gene
expression to cones with human cone opsin promoters in
recombinant AAV. Gene Ther. 2008;15:1049–1055.
57. Ye GJ, Budzynski E, Sonnentag P, et al. Cone-specific
promoters for gene therapy of achromatopsia and other
retinal diseases. Hum Gene Ther. 2016;27:72–82.
58. Porrello K, Bhat SP, Bok D. Detection of interphotoreceptor
retinoid binding protein (IRBP) mRNA in human and cone-
dominant squirrel retinas by in situ hybridization. J Histo-
chem Cytochem. 1991;39:171–176.
59. al-Ubaidi MR, Font RL, Quiambao AB, et al. Bilateral retinal
and brain tumors in transgenic mice expressing simian virus
40 large T antigen under control of the human interphotor-
eceptor retinoid-binding protein promoter. J Cell Biol. 1992;
119:1681–1687.
60. Castle MJ, Turunen HT, Vandenberghe LH, Wolfe JH.
Controlling AAV Tropism in the nervous system with natural
and engineered capsids. Methods Mol Biol. 2016;1382:133–
149.
61. Day TP, Byrne LC, Schaffer DV, Flannery JG. Advances in AAV
vector development for gene therapy in the retina. Adv Exp
Med Biol. 2014;801:687–693.
62. Byrne LC, Visel M, Dufour V, et al. Directed evolution of AAV
vectors guided by deep sequencing creates variants that
bypass structural barriers in canine retina. American Society
of Gene & Cell Therapy 20th Annual Meeting. Mol Ther. 2017;
25:ASGCT E-abstract 505.
63. Petrs-Silva H, Dinculescu A, Li Q, et al. Novel properties of
tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther.
2011;19:293–301.
64. Kay CN, Ryals RC, Aslanidi GV, et al. Targeting photoreceptors
via intravitreal delivery using novel, capsid-mutated AAV
vectors. PLoS One. 2013;8:e62097.
65. McCarty DM. Self-complementary AAV vectors; advances and
applications. Mol Ther. 2008;16:1648–1656.
66. Mowat FM, Gornik KR, Dinculescu A, et al. Tyrosine capsid-
mutant AAV vectors for gene delivery to the canine retina
from a subretinal or intravitreal approach. Gene Ther. 2014;
21:96–105.
67. Beltran WA, Hammond P, Acland GM, Aguirre GD. A
frameshift mutation in RPGR exon ORF15 causes photore-
ceptor degeneration and inner retina remodeling in a model
of X-linked retinitis pigmentosa. Invest Ophthalmol Vis Sci.
2006;47:1669–1681.
68. Beltran WA, Cideciyan AV, Iwabe S, et al. Successful arrest of
photoreceptor and vision loss expands the therapeutic
window of retinal gene therapy to later stages of disease.
Proc Natl Acad Sci U S A. 2015;112:E5844–E5853.
69. Jacobson SG, Cideciyan AV, Aguirre GD, et al. Improvement in
vision: a new goal for treatment of hereditary retinal
degenerations. Expert Opin Orphan Drugs. 2015;3:563–575.
70. Cideciyan AV, Rachel RA, Aleman TS, et al. Cone photorecep-
tors are the main targets for gene therapy of NPHP5 (IQCB1)
or NPHP6 (CEP290) blindness: generation of an all-cone
Nphp6 hypomorph mouse that mimics the human retinal
ciliopathy. Hum Mol Genet. 2011;20:1411–1423.
71. Charng J, Cideciyan AV, Jacobson SG, et al. Variegated yet non-
random rod and cone photoreceptor disease patterns in
RPGR-ORF15-associated retinal degeneration. Hum Mol Gen-
et. 2016;25:5444–5459.
72. Cideciyan AV, Hood DC, Huang Y, et al. Disease sequence
from mutant rhodopsin allele to rod and cone photoreceptor
degeneration in man. Proc Natl Acad Sci U S A. 1998;95:
7103–7108.
73. Cideciyan AV, Jacobson SG, Aleman TS, et al. In vivo dynamics
of retinal injury and repair in the rhodopsin mutant dog
model of human retinitis pigmentosa. Proc Natl Acad Sci U S
A. 2005;102:5233–5238.
74. Jacobson SG, McGuigan DB III, Sumaroka A, et al. Complexity
of the class B phenotype in autosomal dominant retinitis
pigmentosa due to rhodopsin mutations. Invest Ophthalmol
Vis Sci. 2016;57:4847–4858.
75. Jacobs JB, Dell’Osso LF, Hertle RW, Acland GM, Bennett J. Eye
movement recordings as an effectiveness indicator of gene
therapy in RPE65-deficient canines: implications for the
ocular motor system. Invest Ophthalmol Vis Sci. 2006;47:
2865–2875.
76. Porto FBO, Perrault I, Hicks D, et al. Prenatal human ocular
degeneration occurs in Leber’s congenital amaurosis (LCA2). J
Gene Med. 2002;4:390–396.
77. Cideciyan AV, Aleman TS, Boye SL, et al. Human gene therapy
for RPE65 isomerase deficiency activates the retinoid cycle of
vision but with slow rod kinetics. Proc Natl Acad Sci U S A.
2008;105:15112–15117.
78. Georgiadis A, Duran Y, Ribeiro J, et al. Development of an
optimized AAV2/5 gene therapy vector for Leber congenital
amaurosis owing to defects in RPE65. Gene Ther. 2016;23:
857–862.
79. Wojno AP, Pierce EA, Bennett J. Seeing the light. Sci Transl
Med. 2013;5:175fs178.
80. Matulef K, Zagotta WN. Cyclic nucleotide-gated ion channels.
Annu Rev Cell Dev Biol. 2003;19:23–44.
81. Komaromy AM, Rowlan JS, Corr AT, et al. Transient
photoreceptor deconstruction by CNTF enhances rAAV-
mediated cone functional rescue in late stage CNGB3-
achromatopsia. Mol Ther. 2013;21:1131–1141.
Retinal Gene Therapy IOVS j October 2017 j Vol. 58 j No. 12 j 5410
82. Wen R, Song Y, Kjellstrom S, et al. Regulation of rod
phototransduction machinery by ciliary neurotrophic factor.
J Neurosci. 2006;26:13523–13530.
83. Langlo CS, Erker LR, Parker M, et al. Repeatability and longitudinal
assessment of foveal cone structure in Cngb3-associated achro-
matopsia [published online ahead of print January 31, 2017].
Retina. doi:10.1097/IAE.0000000000001434.
84. Banin E, Gootwine E, Obolensky A, et al. Gene augmentation
therapy restores retinal function and visual behavior in a
sheep model of CNGA3 achromatopsia. Mol Ther. 2015;23:
1423–1433.
85. Beltran WA, Cideciyan AV, Lewin AS, Hauswirth WW,
Jacobson SG, Aguirre GD. Gene augmentation for X-linked
retinitis pigmentosa caused by mutations in RPGR. Cold
Spring Harb Perspect Med. 2015;5:a017392.
86. Carvalho LS, Xu J, Pearson RA, et al. Long-term and age-
dependent restoration of visual function in a mouse model of
CNGB3-associated achromatopsia following gene therapy.
Hum Mol Genet. 2011;20:3161–3175.
87. Wu Z, Hiriyanna S, Qian H, et al. A long-term efficacy study of
gene replacement therapy for RPGR-associated retinal degen-
eration. Hum Mol Genet. 2015;24:3956–3970.
Retinal Gene Therapy IOVS j October 2017 j Vol. 58 j No. 12 j 5411
